Apply Now Enquire Now

Dr. Sumedha Mukherjee

Assistant Professor

Dr. Sumedha Mukherjee is currently working as an Assistant Professor in the School of Basic and Applied Sciences. She has a strong research background in drug discovery for cerebral ischemia reperfusion injury. After completing her Ph.D. in Biomedical Engineering from Indian Institute of Technology (BHU), Varanasi, she moved to Liege, Belgium for further post-doctoral research. She explored inhibitors of cell death pathways involved in cancer and neuronal hypoxia during her postdoctoral study in University of Liege. She is a highly passionate researcher and academician. She believes in a holistic teaching approach which not only improves the knowledge of students, but also enhances their critical thinking.

Experience

  • 3 years of post-doctoral experience in university-industry research collaboration

Qualification

  • P.hD in Biomedical Engineering from IIT (BHU)
  • M.Tech. in Biotechnology from Heritage Institute of Technology
  • M.Sc. in Biotechnology from Jadavpur University

Award & Recognition

  • MHRD-GATE Fellowship for pursuing M.Tech and Ph.D.

Research

 Dr. Sumedha Mukherjee is interested in exploring neuro-specific small molecules, phytochemicals and endogenous hormones which might find translational applications in neurodegenerative disorders. In connection to neuroprotective drug discovery, her research explores neuro-pathophysiological, cellular death and cerebral ischemic pathways .She also possess expertise in in-silico drug designing, biomaterials and in-vivo models of neurodegenerative disorders.

Publications

  1. Vermani B1, Mukherjee S1, Kumar G, Patnaik R. Prolactin attenuates global cerebral ischemic injury in rat model by conferring neuroprotection. Brain Injury (IF: 2.3). 2020 Feb 17; 1-9. DOI: 10.1080/02699052.2020.1726466. (1 Equal contribution)
  2. Kumar G, Mukherjee S, Kumar S, Patnaik R. Rapid Determination of Nitrate in Brain Regions and Cerebrospinal Fluid of Transient Bilateral Common Carotid Artery Occlusion Rat Model by HPLC–UV. Proceedings of the National Academy of Sciences, India Section A: Physical Sciences (IF: 1.5). 2020 : 1-8. DOI: 10.1007/s40010-020-00666-0.
  3. Mukherjee S, Kumar G, Patnaik R. Withanolide A penetrates brain via intra-nasal administration and exerts neuroprotection in cerebral ischemia reperfusion injury in mice. Xenobiotica (IF: 1.9). 2019 Dec; 1-29. DOI: 10.1080/00498254.2019.1709228.
  4. Kumar G, Kasiviswanathan U, Mukherjee S, Mahto SK, Sharma N, Patnaik R. Changes in electrolyte concentrations alter the impedance during ischemia-reperfusion injury in rat brain. Physiological measurement (IF: 2.8). 2019 Oct 30;40(10):105004. DOI: 10.1088/1361-6579/ab47ee.
  5. Kumar G, Mukherjee S, Paliwal P, Singh SS, Birla H, Singh SP, Krishnamurthy S, Patnaik R. Neuroprotective effect of chlorogenic acid in global cerebral ischemia-reperfusion rat model. Naunyn-Schmiedeberg's archives of pharmacology (IF: 3.00). 2019 Jun 12:1-7. DOI: 10.1007/s00210-019-01670-x.
  6. Kumar G, Paliwal P, Mukherjee S, Patnaik N, Krishnamurthy S, Patnaik R. Pharmacokinetics and brain penetration study of chlorogenic acid in rats. Xenobiotica (IF: 1.9). 2018 Mar 7:1-7. DOI:10.1080/00498254.2018.1445882.
  7. Mukherjee S, Kumar G, Patnaik R. Identification of potential inhibitors of PARP-1, a regulator of caspase-independent cell death pathway, from Withania somnifera phytochemicals for combating neurotoxicity: A structure-based in-silico study. Journal of Theoretical and Computational Chemistry (IF: 0.939). 2017 Sep 11:1750062. DOI: 10.1142/S0219633617500626.

Patents

Identification of Withafastuosin E as An Inhibitor of Rho-Associated Kinase-2 Catalytic Domain: Potential to Be Developed as Neurotherapeutic agent For Ischemic Stroke. Australian Patent Application Number 2021105021. Filed 2021-08-05 (Granted).

Necroptosis Modulators, Screening Methods and Pharmaceutical Compositions. EP4078183A1 Published 26/10/22.

RIPK1 Modulators, Screening Methods and Pharmaceutical Compositions. 201911053218 Published 25/06/2021.

Necroptosis Modulators, Screening Methods and Pharmaceutical Compositions.WO/2021/123412, Published 24/06/2021.

Necroptosis Modulators, Screening Methods and Pharmaceutical Compositions TW202124418A, Published 01/07/2021.

Modulators Of Necroptosis, Screening Procedures and Pharmaceutical Compositions. AR120850A1, Published 23/03/2022.

Necroptosis Modulators, Screening Procedures and Pharmaceutical Composition. UY39000A, Published 30/07/2021.

Identification of Anti-Covid 19 Agent Somniferine as Inhibitor of Mpro & Ace2-Rbd Interaction. Australian Patent number: 2021104451. Granted: 30.03.2022.

Certifications

Laboratory Animal Science certification for Scientists responsible for directing animal experiments (Maître d'Experience); FELASA (Cat C) from University of Liege.

Area of Interest

  • Neuroscience
  • Cerebral Ischemia
  • Neuropharmacology
  • Therapeutic effects of endogenous hormones
  • Drug designing and Discovery

Book Published

Other Achievements